ARCALIS News and Resources

Meiji Seika Pharma has announced its investment in ARCALIS, a joint venture focused on the development and manufacturing of mRNA vaccines and pharmaceuticals. This collaboration aims to bolster the production of mRNA vaccines in Japan, ensuring faster and more reliable